Jeff Jonas, portfolio manager at Gabelli Funds, said he’s surprised at the drop in Medtronic’s stock on the heels of its “tiny miss” on organic revenue growth. “I don’

The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed to stapling segment pressures, as well as a drop in purchases of its blood oxygen management products because of fewer respiratory-related hospitalizations in the U.S.